Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms

Boehringer Ingelheim

Status and phase

Completed

Phase 4

Conditions

Prostatic Hyperplasia

Treatments

Drug: Matching placebo capsule

Drug: Tamsulosin HCl controlled release capsules

Study type

Interventional

Funder types

Industry

Identifiers

NCT02245490

527.30

Details and patient eligibility

About

Study to evaluate the efficacy of tamsulosin on storage symptoms and detrusor motor activity in patients with LUTS suggestive of BPH and relevant storage symptoms

Enrollment

153 patients

Sex

Male

Ages

50 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male outpatients aged 50-80 years
LUTS suggestive of BPH
Medical history: storage symptoms (frequency, urgency) for at least 6 months
Urinary Chart:
- At least 8 micturitions per 24 hours on average, over the week of the screening period (check urinary chart at Visit 2)
- Urgency (strong desire to void): at least once per 24 hours on average, over the week of the screening period (check urinary chart at Visit 2)
I-PSS ≥ 13 at randomisation (Visit 3)
Qmax: > 4 ml/sec at randomisation (Visit 3), with a voiding volume of at least 150 ml
Prostate Specific Antigen (PSA) < 2.5 ng/ml or between 2.5 and 10 ng/ml, if cancer is ruled out with the usual procedures of each centre (Visit 1; results before Visit 3)
Written Informed Consent for participation to the study

Exclusion criteria

Patients with a known history or a diagnosis at the time of the screening visit (Visit 1) of the following conditions:
Urological disturbances
- Medical history of pelvic surgery
- Palpable bladder at the physical examination, or residue urinary volume > 400 ml
- Known neurological bladder disorder
- Bladder neck stenosis
- Urethral stricture
- Bladder or prostatic cancer
- Bladder stone
- Severe diverticulum of the bladder
- Symptomatic urinary tract infection during last month, or recurrent urinary tract infections (more than 2 during last year)
- Haematuria of unknown origin
- Diseases which may affect micturition (i.e., diabetes mellitus)
Cardiovascular diseases (if they occurred in the last 6 months)
- Myocardial infarction
- Instable angina
- Clinically significant ventricular arrhythmias
- Heart failure (NYHA classes III/IV)
- Orthostatic hypotension
- Cerebral stroke
Neurological diseases (if their severity might compromise the correct performance of the trial)
- Senile dementia
- Multiple sclerosis
- Parkinson's disease
- Psychiatric disturbances
Hepatic or renal insufficiency (biochemistry values 15% outside normal lab ranges, being regarded as clinically relevant by the investigator)
Clinically significant abnormality in the haematological, blood chemistry and urinary values evidenced on the samples taken at the screening visit (Visit 1)
Patients who are taking or have been taking α-blockers for BPH or for hypertension, or phytotherapy for BPH within the previous 6 weeks
Patients who were taking or have been taking:
- α-blockers for BPH or for hypertension within the previous 4 weeks
- phytotherapy for BPH or mepartricin within the previous 4 weeks
- finasteride within the previous 6 months
- anticholinergics within the previous 4 weeks
- antidiuretics within the previous 4 weeks
- concomitant drugs which may influence the pharmacodynamic or pharmacokinetic properties of tamsulosin. In particular: α-blockers and mixed α-β-blockers, α- agonists, anti-cholinergics
Patients who are or have been taking part in a clinical study within the previous 3 months
Patients who have had hypersensitivity or allergic reactions to previously prescribed α- blocker(s)
Patients judged by the investigator to be inappropriate for inclusion in the study